Evidence map›Paper›PMID 35475667›Full record

ArticleJournal of virology2022

Impact of Micropolymorphism Outside the Peptide Binding Groove in the Clinically Relevant Allele HLA-C*14 on T Cell Responses in HIV-1 Infection.

Takayuki Chikata, Wayne Paes, Nozomi Kuse, Thomas Partridge, Hiroyuki Gatanaga, Yu Zhang, Kimiko Kuroki, Katsumi Maenaka, Nicola Ternette, Shinichi Oka and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Takayuki ChikataTokyo Laboratory and Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Wayne PaesNuffield Department of Clinical Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Nozomi KuseTokyo Laboratory and Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Thomas PartridgeNuffield Department of Clinical Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Hiroyuki GatanagaTokyo Laboratory and Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Yu ZhangTokyo Laboratory and Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Kimiko KurokiLaboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Katsumi MaenakaLaboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido Universitygrid.39158.36, Sapporo, Japan.
Nicola TernetteNuffield Department of Clinical Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.ORCID 0000-0002-9283-0743
Shinichi OkaTokyo Laboratory and Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.
Persephone BorrowNuffield Department of Clinical Medicine, University of Oxfordgrid.4991.5, Oxford, United Kingdom.
Masafumi TakiguchiTokyo Laboratory and Division of International Collaboration Research, Joint Research Center for Human Retrovirus Infection, Kumamoto Universitygrid.274841.c, Kumamoto, Japan.ORCID 0000-0002-8516-6442
Kumamoto University · JPUniversity of Oxford · GBHokkaido University · JPNational Center for Global Health and Medicine · JP

Funding

Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccinesR01AI118549 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2016 to 2020
$3.6M
HHS | National Institutes of Health (NIH) R01 AI 118549NIAID NIH HHS R01 AI118549UKRI | Medical Research Council (MRC) MR/K012037
6 · The paper itself

Abstract

There is increasing evidence for the importance of human leukocyte antigen C (HLA-C)-restricted CD8

Indexed as

CD8-Positive T-LymphocytesHIV InfectionsHIV SeropositivityHLA-C AntigensAllelesEpitopes, T-LymphocyteHIV-1HumansPeptidesEpitopes, T-LymphocyteHLA-C AntigensPeptidesCD8+ T cellsepitopesHIV-1HLA-CLC-MS/MSpeptides

Identifiers

PMID35475667
PMCPMC9131871
OpenAlexW4225000375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.